EBS - Why Emergent BioSolutions Stock Dropped 30% in April
Shares of Emergent BioSolutions (NYSE: EBS) fell 30% in April, according to data from S&P Global Market Intelligence , after quality-control errors at one of the company's facilities ruined millions of doses of Johnson & Johnson 's COVID-19 vaccine.
The purge was required after ingredients of another vaccine had contaminated the production area of J&J's shot.
Image source: Getty Images.
For further details see:
Why Emergent BioSolutions Stock Dropped 30% in April